A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
I. To determine the correlation of the data from the frailty index and geriatric assessment
tool with the level of toxicity encountered in the first two cycles of therapy.
Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy.
Patients receive standard-of-care chemotherapy comprising carboplatin intravenously (IV) and
paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Use of the Frailty Index and/or the geriatric assessment in prediction of toxicity
Prior to chemotherapy
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
|Wake Forest University Health Sciences||Winston-Salem, North Carolina 27157|
|Syracuse VA Medical Center||Syracuse, New York 13210|